1. Show article details.

    Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results

    PR Newswire – 4:28 PM ET 03/04/2015

    ATLANTA, March 4, 2015Alimera Sciences, Inc. (ALIM), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and year ended December 31, 2014.

  2. Show article details.

    Alimera Sciences To Release Fourth Quarter And Fiscal Year 2014 Financial Results

    PR Newswire – 4:05 PM ET 02/23/2015

    ATLANTA, Feb. 23, 2015Alimera Sciences, Inc. (ALIM), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2014 financial results after the market close on Wednesday, March 4, 2015.

  3. Show article details.

    Alimera Sciences To Present At 2015 Cowen Healthcare Conference

    PR Newswire – 4:01 PM ET 02/23/2015

    ATLANTA Alimera Sciences, Inc. (ALIM), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Rick Eiswirth, Chief Operating Officer and Chief Financial Officer, will present at the 2015 Cowen Healthcare Conference on Monday, March 2, 2015 at 2:50 p.m. ET at The Boston Marriott Copley Place in Boston...

  4. Show article details.

    Alimera Sciences To Host ILUVIEN® Live Webinar Launch Event

    PR Newswire – 8:00 AM ET 02/17/2015

    ATLANTA, Feb. 17, 2015 Alimera Sciences, Inc. (ALIM), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced it will host a live webinar for eye care professionals on Monday, March 2, 2015, at 8:30 p.m. EST, during which eight leading retinal specialists and one glaucoma specialist from around the countr...

  5. Show article details.

    How it All Plays Out: Research Reports on Align Technology, Alimera, Alkermes, Alliance HealthCare Services, and Allied Healthcare Products

    PR Newswire – 8:50 AM ET 02/03/2015

    NEW YORK, February 3, 2015 Moments ago, Analysts Review released new research updates concerning several important developing situations including Align Technology (ALGN), Alimera (ALIM), Alkermes (ALKS), Alliance HealthCare Services (AIQ), and Allied Healthcare Products (AHPI). To access our full PDF reports on a complementary basis, please visit the links below.

  6. Show article details.

    Alimera Sciences' ILUVIEN® Receives Marketing Authorization in Finland and Luxembourg

    PR Newswire – 2:00 PM ET 01/26/2015

    ATLANTA, Jan. 26, 2015 Alimera Sciences, Inc. (ALIM), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that marketing authorization has been granted by the Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg to ILUVIEN® for the treatment of vision impairment associated wit...

  7. Show article details.

    Alimera Sciences Announces First Sale of ILUVIEN® in Portugal

    PR Newswire – 11:48 AM ET 01/14/2015

    ATLANTA, Jan. 14, 2015 Alimera Sciences, Inc. (ALIM), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals today announced that the first unit of ILUVIEN® has been sold in Portugal for the treatment of vision impairment associated with chronic diabetic macular edema insufficiently responsive to available treatments.

  8. Show article details.

    Alimera Sciences Added to NASDAQ Biotechnology Index

    PR Newswire – 8:30 AM ET 12/16/2014

    ATLANTA, Dec. 16, 2014Alimera Sciences, Inc. (ALIM), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has been added to the NASDAQ Biotechnology Index.

  9. Show article details.

    Alimera Sciences Announces Closing of $50.0 Million Financing with Deerfield Management

    PR Newswire – 8:45 AM ET 12/15/2014

    ATLANTA, Dec. 15, 2014 Alimera Sciences, Inc. (ALIM), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has closed its offering of Series B Preferred Stock with Deerfield Management and certain of its affiliates.

  10. Show article details.

    Annual Changes to the NASDAQ Biotechnology Index

    GlobeNewswire – 7:10 AM ET 12/15/2014

    The NASDAQ OMX Group, Inc. (NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index, which will become effective prior to market open on Monday, December 22, 2014.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Mar
    4

    ALIM Earnings Conference Call at 4:30 PM Listen

  • Mar
    4

    ALIM announced Q4 earnings of -$0.28 per share (vs. -$0.160) at 3/4/2015 4:28:00 PM ET

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.